These animal studies support the hypothesis that mTOR activation is responsible for the ASD-associated phenotypes in TSC [16, 26, 42] and thereby mTOR inhibition might be an effective treatment strategy for ASD symptoms in TSC patients [10, 25]. This evidence concerns the gene MTOR and tuberous sclerosis.